Template:Rifampin isoniazid pyrazinamide: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) m Gerald Chi moved page Template:Isoniazid to Template:Rifampin isoniazid pyrazinamide without leaving a redirect |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | {| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | ||
|- | |||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Isoniazid|{{fontcolor|#6C7B8B|Isoniazid}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Isoniazid|{{fontcolor|#6C7B8B|Isoniazid}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left |RIFATER <sup>®</sup> FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left |RIFATER <sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide description|Description]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide microbiology|Microbiology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide indications and usage|Indications and Usage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide contraindications|Contraindications]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide warnings and precautions|Warnings and Precautions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide adverse reactions|Adverse Reactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide clinical studies|Clinical Studies]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide how supplied|How Supplied]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[ | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid pyrazinamide labels and packages|Labels and Packages]] | ||
|- | |- | ||
|} | |} |